The INSPiRe Programme: Developing an Intensive Suicide Prevention Therapy for Suicidal Prisoners

August 9, 2019 updated by: Jessica Killilea, University of Manchester

The INSPiRe Programme: A Feasibility and Acceptability Study of Intensive Suicide Prevention Therapy in Prison

This study aims to assess the acceptability and feasibility of a short-term, intensive Cognitive Behavioural Therapy (CBT) delivered to male prisoners who have thoughts of ending their lives.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

10 hours of an adapted CBT therapy for suicide will be delivered across 2 weeks in 5 2 hour sessions to male prisoners. They will initially be assessed on several measures of mood, social support and suicidality. They will then undergo therapy. Following this they will be asked to re-completed the initial measures and a post-therapy interview to ascertain their thoughts on their experience of the therapy.

Study Type

Interventional

Enrollment (Actual)

13

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Greater Manchester
      • Warrington, Greater Manchester, United Kingdom, WA3 6BP
        • HMP Risley

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

21 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

Male

Description

Inclusion Criteria:

  • Aged over 21 years old.
  • Has been managed under the Assessment, Care in Custody, and Teamwork (ACCT) system within the last 1 month (including current ACCT review).
  • Sufficient English language proficiency, as judged by the researcher, in order to complete psychometric questionnaires (i.e. adequate reading comprehension) and engage in intensive CBT programme (i.e. adequate verbal communication).
  • Adult is able to provide informed consent as established during baseline clinical interview (BPS, 2006; MCA, 2005).
  • Currently residing in HM Prison (and expected to remain there for at least six weeks; determined through staff and prisoner report).

Exclusion Criteria:

  • A primary organic disorder (indicated by prison medical staff report or records).
  • Any current risk behaviour which would compromise the safety of others, as identified by prison staff.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Intervention
10 hours of intensive CBT for suicide will be delivered to male prisoners who are having thoughts of ending their lives. This will be delivered in 2 hours sessions, 5 times across 2 weeks.
Intensive CBT for suicide

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
The Client Satisfaction Questionnaire (CSQ-8)
Time Frame: 20 minutes
A measure of participant satisfaction with therapy
20 minutes
Therapist Session Summary
Time Frame: 5 minutes
Measuring levels of adherence and engagement
5 minutes
Discharge summary sheet
Time Frame: 15 minutes
Capturing individuals' adherence to the programme or discharge from it
15 minutes
Therapist Rating Form
Time Frame: 20 minutes
Giving an overall picture of each individual's engagement and progress during the study.
20 minutes
Post-intervention interview
Time Frame: 1 hour
Qualitative interview to explore the participant's experience of therapy
1 hour

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Daniel Pratt, University of Manchester
  • Study Chair: Yvonne Awenat, University of Manchester
  • Study Chair: Charlotte Lennox, University of Manchester

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

June 1, 2018

Primary Completion (Actual)

April 26, 2019

Study Completion (Actual)

April 26, 2019

Study Registration Dates

First Submitted

March 19, 2018

First Submitted That Met QC Criteria

April 13, 2018

First Posted (Actual)

April 17, 2018

Study Record Updates

Last Update Posted (Actual)

August 12, 2019

Last Update Submitted That Met QC Criteria

August 9, 2019

Last Verified

August 1, 2019

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 238927

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Suicide

Clinical Trials on INSPiRe Programme

3
Subscribe